32
Participants
Start Date
May 31, 2008
Primary Completion Date
November 30, 2009
Study Completion Date
December 31, 2009
bevirimat dimeglumine
Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
bevirimat dimeglumine
Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
AIDS Research Initiative, Darlinghurst
Holdsworth House Medical Practice, Darlinghurst
St Vincent's Hospital, Darlinghurst
Taylor Square Private Clinic, Darlinghurst
Lead Sponsor
Myrexis Inc.
INDUSTRY